INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58401, 4017, 'Isosorbide mononitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58402, 4018, 'Isosorbide mononitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58403, 4019, 'Isosorbide mononitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58404, 4020, 'Isosorbide mononitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58405, 4021, 'Isosorbide mononitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58406, 4017, 'Isosorbide mononitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58407, 4018, 'Isosorbide mononitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58408, 4019, 'Isosorbide mononitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58409, 4020, 'Isosorbide mononitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58410, 4021, 'Isosorbide mononitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58411, 4017, 'Isosorbide mononitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58412, 4018, 'Isosorbide mononitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58413, 4019, 'Isosorbide mononitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58414, 4020, 'Isosorbide mononitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58415, 4021, 'Isosorbide mononitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58416, 4017, 'Isosorbide mononitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58417, 4018, 'Isosorbide mononitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58418, 4019, 'Isosorbide mononitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58419, 4020, 'Isosorbide mononitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58420, 4021, 'Isosorbide mononitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58421, 4017, 'Isosorbide mononitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58422, 4018, 'Isosorbide mononitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58423, 4019, 'Isosorbide mononitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58424, 4020, 'Isosorbide mononitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58425, 4021, 'Isosorbide mononitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58426, 4017, 'Isosorbide mononitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58427, 4018, 'Isosorbide mononitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58428, 4019, 'Isosorbide mononitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58429, 4020, 'Isosorbide mononitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58430, 4021, 'Isosorbide mononitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58431, 4017, 'Isosorbide mononitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58432, 4018, 'Isosorbide mononitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58433, 4019, 'Isosorbide mononitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58434, 4020, 'Isosorbide mononitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58435, 4021, 'Isosorbide mononitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58436, 0, 'Isradipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58437, 0, 'Isradipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58438, 0, 'Isradipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58439, 0, 'Isradipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58440, 0, 'Isradipine', 'Intestinal Obstruction', 'The controlled-release formulation of isradipine (Dynacirc CR) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-release formulation of isradipine should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58441, 1691, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58442, 2421, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58443, 3701, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58444, 8563, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58445, 8564, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58446, 14165, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58447, 14166, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58448, 15457, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58449, 25293, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58450, 25294, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58451, 26561, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58452, 26562, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58453, 30085, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58454, 30086, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58455, 1691, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58456, 2421, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58457, 3701, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58458, 8563, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58459, 8564, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58460, 14165, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58461, 14166, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58462, 15457, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58463, 25293, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58464, 25294, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58465, 26561, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58466, 26562, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58467, 30085, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58468, 30086, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58469, 1691, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58470, 2421, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58471, 3701, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58472, 8563, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58473, 8564, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58474, 14165, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58475, 14166, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58476, 15457, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58477, 25293, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58478, 25294, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58479, 26561, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58480, 26562, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58481, 30085, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58482, 30086, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58483, 1691, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58484, 2421, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58485, 3701, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58486, 8563, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58487, 8564, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58488, 14165, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58489, 14166, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58490, 15457, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58491, 25293, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58492, 25294, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58493, 26561, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58494, 26562, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58495, 30085, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58496, 30086, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58497, 1691, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58498, 2421, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58499, 3701, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58500, 8563, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '', 'DDInter', 0);
